Liraglutide randomized trial initiated to assess inflammation attenuation in brain-dead organ donors

Brain death is associated with significant inflammation, which negatively impacts the viability and outcomes of transplanted organs. While observational studies suggest target-guided therapies can reduce donor loss and increase organ pick-up rates, no direct studies have tested anti-inflammatory and anti-apoptotic drugs in brain-dead donors to reduce organ inflammation. This gap highlights a critical need for interventions that can preserve organ quality prior to transplantation, addressing a major challenge in organ transplantation and donor management.

This study is a randomized clinical trial designed to evaluate the use of liraglutide in patients with brain death. The trial aims to directly test liraglutide's ability to attenuate the inflammation induced by encephalic death. The primary endpoint will be the assessment of inflammatory markers in organs destined for transplantation. The study will compare liraglutide administration against a control arm, likely standard care, to determine its efficacy in mitigating donor-induced inflammation and potentially improving organ quality for recipients.

This research is a study protocol for a randomized clinical trial, and as such, it does not present completed findings or numerical results. The study's primary objective is to evaluate whether liraglutide can attenuate the inflammation induced by brain death in potential organ donors. The abstract explicitly states that "no study so far has directly tested the effect of drugs with anti-inflammatory and anti-apoptotic properties administered to the donor in encephalic death in reducing inflammation of organs to be transplanted." Therefore, the trial aims to fill this knowledge gap by assessing liraglutide's impact on inflammatory markers in donor organs. The anticipated outcome, if successful, would be a reduction in inflammation, potentially leading to improved organ viability and transplant success rates.